BridgeBio Pharma (2CL) Q3 2026 Earnings Report
DE:2CL Q3 2026 EPS Results
- Actual EPS
- -EUR 0.38
- Consensus EPS
- -EUR 0.49
- Beat/Miss
- Beat by +EUR 0.11
- One Year Ago EPS
- -EUR 0.85
DE:2CL Q3 2026 Revenue Results
- Actual Revenue
- EUR 316.23M
- Expected Revenue
- EUR 262.77M
- Beat/Miss
- Beat by +EUR 53.46M
- YoY Revenue Growth
- +192.60%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- After Close
- Conference Call
- Thursday, October 29, 2026
BridgeBio Pharma's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive, with substantial Attruby revenue growth, favorable real-world and clinical evidence, a $1.5 billion cash position, improved operating results and three potential product launches within seven months. The company also advanced encaleret into a Phase III chronic hypoparathyroidism study and expanded its pipeline. The main negatives were higher operating expenses, continued operating losses, a large portion of prescribers not yet using Attruby, limited visibility into market share pending Pfizer's results, and the later European filing timeline for BBP-418.
Management said Attruby is tracking to meet or beat its $4 billion peak year sales assumption, with $4 billion in peak year sales across the other 3 brands, and that $25 million to $30 million is the right number near term for sequential revenue growth, with the number eventually going up more from there. The company expects 3 launches in the next 7 months: BBP-418 on November 27, infigratinib on February 4, 2027, and encaleret on May 8, 2027; it expects to reach at least 90% of MDA centers by PDUFA for BBP-418, fully penetrate the 500 identified patient pool by year 3, submit an MAA for BBP-418 in the first half of 2028, and submit top-line FORTIFY month 36 results in late '27 or early '28. Management anticipates OpEx will catch up in the fourth quarter of this year, followed by a more modest steady growth paired with improvement of the operating line throughout 2027 and beyond; it expects to average an operating loss of around $90 million to $100 million a quarter this year versus about $130 million loss a quarter last year, move towards a breakeven point throughout 2027, and reach 2028 where all 4 of the brands have a chance to be profitable on a stand-alone basis. RECLAIM-HP will enroll approximately 160 individuals, with top line results anticipated in the next 15 months.
- Attruby Revenue Growth and Commercial MomentumU.S. Attruby net product revenue was $253.2 million, up approximately 14% quarter-on-quarter and approximately 134% year-over-year. Growth was predominantly driven by first-line new starts, with approximately 2,900 physicians having tried Attruby. Management said new prescribers using Attruby continue to expand each quarter, while gross-to-net, persistency and compliance rates remain stable and strong.
- BEYONTTRA Global Performance and Milestone RevenueThe Attruby BEYONTTRA franchise is annualizing to over $1 billion in the U.S. market and well over that globally. BEYONTTRA was described as the leading brand in Europe, and BridgeBio recorded $75 million in one-time license revenue from a Bayer sales milestone, along with $20.5 million in royalty revenue compared with $4.3 million in the prior-year quarter.
- Attruby Peak Sales OutlookManagement said Attruby is tracking to meet or beat its $4 billion peak-year sales assumption. Near-term sequential growth was described as approximately $25 million to $30 million, with the possibility of increasing over time.
- Real-World Evidence Favoring AcoramidisA Komodo U.S. claims analysis showed acoramidis significantly reduced the risk of early clinical worsening versus tafamidis, including a 34% reduction in composite clinical worsening and a 43% reduction in diuretic intensification. An independent Epic Cosmos analysis of 2,684 propensity-score-matched ATTR-CM patients showed an 18% lower risk of death, all-cause hospitalization, new-onset atrial fibrillation or diuretic intensification, along with 25% to 27% lower risks of all-cause, cardiovascular and heart-failure hospitalization.
- Clinical Evidence for Cardiac and Kidney BenefitsIn the ATTRibute-CM study, clinically meaningful improvement in left ventricular systolic function occurred in 54% of acoramidis-treated participants versus 20% of placebo-treated participants at month 30. Participants treated with acoramidis gained 65 additional days alive and out of the hospital by month 36. Management also described a sustained reduction in eGFR slope decline over 30 months and a kidney-protective effect associated with acoramidis.
- Progress in ATTR Development PipelineBridgeBio dosed the first participant in ASCEND-ATTR, a Phase IIIb/IV study evaluating cardiac structure, function and amyloid burden over 36 months. The company also nominated BBP-717, a next-generation monoclonal antibody depleter for ATTR cardiomyopathy, as a development candidate and plans an IND in 2027.
- Three Near-Term Launch OpportunitiesManagement highlighted three potential launches within the next seven months: BBP-418 for LGMD2I, infigratinib for achondroplasia and encaleret for ADH1. All three NDAs received priority review, with PDUFA dates of November 27, February 4, 2027 and May 8, 2027, respectively.
- BBP-418 Regulatory and Clinical ProgressBBP-418 has a November 27 PDUFA date, with no advisory committee planned, and management said the program is on track for a traditional full approval. In the FORTIFY interim analysis, the study met every primary and secondary endpoint at 12 months, with treated participants improving while placebo participants declined across every key measure.
- BBP-418 Cardiac Data and Patient IdentificationAmong LGMD2I participants with elevated high-sensitivity troponin I at baseline, 100% of BBP-418-treated participants returned to the normal range by month 12 versus 40% on placebo. Stable or improved ejection fraction was observed in 54% of treated participants versus 25% on placebo. The company has identified more than 500 U.S. patients and expects to reach at least 90% of MDA Care Centers by PDUFA.
- BBP-418 Launch ReadinessBBP-418 is manufactured and ready to go in channel. Neuromuscular account managers had reached more than 70% of MDA Care Centers and were expected to reach at least 90% by PDUFA. BridgeBio also launched the Type Hype patient-facing campaign to encourage genetic testing among people with suspected LGMD.
- Infigratinib Regulatory and Clinical PositioningThe FDA accepted the infigratinib NDA with priority review and set a February 4, 2027 PDUFA date. BridgeBio said infigratinib could launch as the only oral product for achondroplasia less than 12 months after the latest commercial injectable entered the market. PROPEL 3 remains the only achondroplasia Phase III study published in the New England Journal of Medicine and the only program with placebo-controlled efficacy beyond annualized height velocity at 52 weeks.
- Additional Infigratinib BenefitsOver 52 weeks, children receiving oral infigratinib had a 38% lower rate of ear infections than placebo, while sleep apnea measures remained stable compared with a 49% increase on placebo. The company has submitted an MAA to the EMA and anticipates potential European approval in the second half of 2027.
- Encaleret Regulatory and Patient Identification ProgressEncaleret is under priority review for ADH1 with a May 8, 2027 PDUFA date and no advisory committee planned. It would be the first therapy specifically indicated for ADH1 in the United States and Europe. BridgeBio has identified more than 600 genetically confirmed patients, up from approximately 500 last quarter, and has submitted an MAA to the EMA.
- Encaleret Clinical Evidence in ADH1In CALIBRATE, encaleret was associated with an eGFR change of plus 11 versus plus 3 ml per minute per 1.73 meter squared at week 24 compared with conventional therapy. It restored bone turnover by restoring the bone's own PTH production, and 100% of participants reported improvement in at least one ADH symptom versus 46% on standard of care.
- Expansion into Chronic HypoparathyroidismBridgeBio dosed the first participant in RECLAIM-HP, a global registrational Phase III study of encaleret in chronic hypoparathyroidism. The condition affects approximately 200,000 patients in the U.S. and EU, compared with an estimated 25,000 prevalent ADH1 patients in those geographies. The study will enroll approximately 160 individuals, with a primary endpoint of concomitant blood and urine calcium normalization at week 24. Top-line results are anticipated in the next 15 months.
- Improved Financial Results and Cash PositionThird-quarter total revenue was $353.2 million versus $120.7 million in the prior-year period. The operating loss narrowed to $11.6 million from $145.2 million. Cash, cash equivalents and marketable securities totaled $1.5 billion at September 30, 2026, described as the strongest reported cash position in company history.
- Financial Flexibility and Capital AllocationManagement said the $1.5 billion cash position and improving financial trajectory fully resource the upcoming launches, continued Attruby investment, label expansion and life-cycle management. The company also reiterated its approach of funding operations first, then considering cash retention, pipeline growth through M&A or sister-company integration, and share buybacks; BridgeBio bought back shares in September.
DE:2CL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.53- | -0.9 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | -0.49-0.38 | -0.85 | 55.79% (+0.47) | |
| Aug 10, 2026 | 2026 (Q2) | -0.52-0.70 | -0.85 | 17.89% (+0.15) | |
| May 07, 2026 | 2026 (Q1) | -0.61-0.75 | -0.79 | 4.55% (+0.04) | |
| Feb 24, 2026 | 2025 (Q4) | -0.64-0.90 | -1.25 | 28.57% (+0.36) | |
| Oct 29, 2025 | 2025 (Q3) | -0.80-0.85 | -0.77 | -10.47% (-0.08) | |
| Aug 05, 2025 | 2025 (Q2) | -0.71-0.85 | -0.35 | -143.59% (-0.50) | |
| Apr 29, 2025 | 2025 (Q1) | -0.82-0.79 | -0.18 | -340.00% (-0.61) | |
| Feb 20, 2025 | 2024 (Q4) | -1.00-1.25 | -0.86 | -45.83% (-0.39) | |
| Nov 12, 2024 | 2024 (Q3) | -0.90-0.77 | -0.97 | 20.37% (+0.20) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
